To validate ROCK2 as a therapeutic target for TLE, we established pilocarpine‐induced acute TLE mouse models and randomly assigned mice into two groups: one group received the ROCK2 inhibitor belumosudil (the ROCK2 group), and the other received saline as a control (the epilepsy model (EP) group). Here, ROCK2 is linked to epilepsy.